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Protein kinases play important regulatory roles in
cells and organisms. Therefore, they are subject to
specific and tight mechanisms of regulation that ulti-
mately converge on the catalytic domain and allow
the kinases to be activated or inhibited only upon
the appropriate stimuli. AGC protein kinases have a
pocket in the catalytic domain, the PDK1-interacting
fragment (PIF)-pocket, which is a key mediator of
the activation. We show here that helix aC within
the PIF-pocket of atypical protein kinase C (aPKC)
is the target of the interactionwith its inhibitory N-ter-
minal domains. We also provide structural evidence
that the small compound PS315 is an allosteric inhib-
itor that binds to the PIF-pocket of aPKC. PS315 ex-
ploits the physiological dynamics of helix aC for its
binding and allosteric inhibition. The results will sup-
port research on allosteric mechanisms and selec-
tive drug development efforts against PKC isoforms.
INTRODUCTION
Cellular functions are regulated by numerous signaling mecha-
nisms. Many of these regulatory mechanisms ultimately rely on
conformational changes in the proteins that transfer information
through signaling cascades to the effector molecules. Protein
kinases, intermediate signaling molecules, are tightly regulated
by activating and inhibitory mechanisms that allosterically
converge on the catalytic domain (Huse and Kuriyan, 2002; Paw-
son and Scott, 2005). The overall structure of the catalytic
domain is highly conserved throughout the protein kinase family.
It consists of a bilobal domain with a small lobe and a large lobe
(Figure 1A), with the ATP-binding site situated between the two
lobes and the substrate peptide-binding site mostly located on
the large lobe (Knighton et al., 1991).
AGC kinases (a group of protein kinases comprising the
protein kinase A (PKA), protein kinase G, and protein kinase C754 Chemistry & Biology 21, 754–765, June 19, 2014 ª2014 Elsevier(PKC) families) typically have three conserved phosphorylation
sites (Newton, 2010; Parker and Parkinson, 2001; Vanhaese-
broeck and Alessi, 2000). The first is located in the activation
loop and, when phosphorylated, links the small and large lobes
of the kinase domain, closing the structure and stabilizing the
active conformation. The other two conserved phosphorylation
sites are located in the region C-terminal to the kinase domain.
The turn motif (also termed ‘‘zipper’’) and the hydrophobic motif
(HM) phosphorylation sites, when phosphorylated, allow the
interaction of the C terminus with phosphate-binding sites on
the small lobe and support the binding of the HM (Phe-Xaa-
Xaa-Phe, Figure 1A) to the PDK1-interacting fragment (PIF)-
pocket located on the small lobe between the aC helix and
b sheets 4 and 5 (Arencibia et al., 2013; Hauge et al., 2007).
The PIF-pocket of 3-phosphoinositide-dependent protein ki-
nase 1 (PDK1) allows for substrate docking (Biondi et al., 2001)
and allosteric stimulation of kinase activity (Biondi et al., 2000;
Hindie et al., 2009). The equivalent PIF-pocket site in other
AGC kinase families, such as S6K, serum- and glucocorticoid-
stimulated kinase, protein kinase B (PKB)/Akt, p90 ribosomal
S6 kinase, and mitogen- and stress-activated protein kinase,
is critical for activation by HM phosphorylation (Fro¨din et al.,
2002; Yang et al., 2002). Phosphorylation of the HM (Phe-Xaa-
Xaa-Phe-Ser/Thr-Tyr/Phe) triggers the intramolecular interaction
of the HM, with the Phe residues docking into the hydrophobic
PIF-pocket. Indeed, the crystal structures of active AGC kinases
reveal that the Phe residues of the HM bind to the PIF-pocket
(Pearce et al., 2010). The key function of this particular pocket
was confirmed by the development of small molecules that
bind to the PIF-pocket of PDK1 and, thereby, activate the kinase
in vitro (Engel et al., 2006; Wei et al., 2010), stabilizing local and
allosteric conformational changes thatmimic the effects of phos-
phorylation (Busschots et al., 2012; Hindie et al., 2009).
Members of the protein kinase C (PKC) family are regulated by
phosphorylation and by an N-terminal extension of the catalytic
domain (Newton, 2010). All PKCs contain a pseudosubstrate
region (PSR) and a contiguous C1 domain. Conventional PKCs
have two C1 domains and one C2 domain, novel PKCs possess
two C1 domains and one novel C2 domain, and atypical PKCs
(aPKCs) contain a PSR that is connected to a single atypical
C1 domain (see Figure 1B). It is thought that the PSR bindsLtd All rights reserved
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Figure 1. The Domain Structure of PKC Isoforms and the Atypical PKC Constructs Used in This Study
(A) The structure of the catalytic domain of PKCi (PDB code 3A8W) (Takimura et al., 2010). The PIF-pocket, indicated by a box, is the physiological binding site of
the C-terminal HM. Phe residues of the HM are represented as red sticks.
(B) A schematic overview of the PKC isoforms indicates the different domains present in the classical, novel, and atypical PKCs (C2, C2 domain; C1, C1 domain;
PB1, PB1 domain; Cat. Domain, protein kinase catalytic domain) and the full-length and truncated constructs of atypical PKCs used in this study. PKMz
corresponds to a splicing variant of PKCz that lacks all N-terminal regulatory domains. The equivalent regulatory domains within the different PKC isoforms are
the PSRs and their contiguous C1 domains (C1A domains in classical and novel PKCs).
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Mechanism of Allosteric Inhibition of aPKCsubstrate-like (pseudosubstrate) to the peptide-substrate bind-
ing site of PKCs and that this inhibition is released by the binding
of second messengers, such as Ca2+ and diacylglycerol, to the
C1 and C2 domains of conventional PKCs. More recently, we
identified that the C1 domain of the atypical PKCz isoform also
plays a key role in the inhibition of the activity, acting together,
as a block, with the pseudosubstrate (Lopez-Garcia et al.,
2011). Atypical PKC isoforms play an important role in cellular
polarization. A splice variant of PKCz, protein kinase M (PKM)
z, which lacks the N-terminal regulatory regions, is expressed
in neurons and is necessary for long-term memory and long-
term potentiation and participates in chronic pain (Price and
Ghosh, 2013). On the other hand, the PKCi isoform has been
more widely validated as a drug target for cancers (Atwood
et al., 2013; Murray et al., 2011).
Here we identify helix aC as a key mediator of aPKC mecha-
nism of inhibition by the N-terminal domains and determine
that the PIF-pocket is a specific binding site for small com-
pounds that allosterically inhibit aPKCs. We conclude that the
PIF-pocket has evolved as a critical mediator of the regulation
of AGC kinases by transducing signals from secondmessengers
and posttranslational modifications into conformational changes
that either activate or inhibit the target kinase. Notably, this
work provides structural and molecular information for the
development of small allosteric compounds that modulate the
conformation of signaling molecules, thereby aiding future drug
development efforts toward targeting allosteric proteins.
RESULTS
The N-terminal Domains Protect Two Regions of the
PKCi Catalytic Domain
To study the inhibitory effects of the N-terminal extension
of PKCi on its catalytic domain, we expressed purified andChemistry & Biology 21,biochemically characterized full-length and truncated catalytic
domain constructs of PKCz and PKCi (Figure 1B; Figure S1
available online). We selected PKCi for further studies because
this isoform could be obtained in higher homogeneity, was
monomeric, and was stable under the experimental conditions
required. To analyze the dynamic of the proteins in solution, we
made use of the ability of backbone amide hydrogens to be
exchanged for deuteriums, depending on their exposure to
the deuterated solvent. For hydrogen/deuterium (1H/2H) ex-
change experiments, PKCi 1–587 and PKCi D223 (Figure 1B)
were incubated for various times in a buffer containing 2H2O.
Subsequently, the isotopic exchange was quenched by acidifi-
cation, the protein was subjected to proteolysis, and the poly-
peptides corresponding to the catalytic domain were analyzed
by mass spectroscopy. We identified 81% common polypep-
tides from the catalytic domain, which we then used for the
comparisons (Figure S2). The 1H/2H exchange data demon-
strate that most of the identified polypeptides from the catalytic
domain had similar 1H/2H exchange patterns (e.g., polypep-
tides 233–246, 247–260, 248–259, 261–273, and 261–285; Fig-
ure S3), indicating that they were not affected by the presence
of the N-terminal region. However, a significant protection
was observed in overlapping polypeptides from the catalytic
domain that corresponded to two distinct regions: region 1,
located at the interphase between the small and large lobes
and encompassing amino acid sequences from helix aC, helix
aE, and the DFG motif (DYG in PKCi), and region 2, located on
the large lobe and encompassing sequences from the P+1 loop
and part of helix aF (Figure 2). Within region 1 of PKCi D223,
a 20-amino acid polypeptide comprising the entire helix aC
(286–306, Figure 2C) and five residues from the following
loop exchanged 12 1H for 2H (12 out of an experimental
maximum of 14.9) after a 10 s incubation, indicating that the
region is highly exposed to solvent. Only a single additional754–765, June 19, 2014 ª2014 Elsevier Ltd All rights reserved 755
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Figure 2. Deuterium Incorporation Levels of
PKCi D223 and PKCi 1–587
The proteins were incubated in deuterated buffer,
and the exchange of hydrogen (1H) for deuterium
(2H) was analyzed by mass spectrometry after
protease cleavage. We identified polypeptides
covering 81% of the isolated catalytic domain of
PKCi (Figure S3). A subset of polypeptides was
protected from 1H/2H exchange in full-length PKCi
(PKCi 1–587) in comparison with the isolated
catalytic domain (PKCi D223).
(A) The catalytic domain of PKCi (PDB code
3A8W), indicating the location of polypeptides that
were protected from 1H/2H exchangemainly in two
distinct regions (boxed). Region 1 encompasses
amino acid sequences from the aC and aE helix
and the DFG motif (DYG in PKCi) located at
the interphase between the small and large lobe.
Region 2 encompasses sequences from the P+1
loop and part of helix aF located on the large lobe.
(B–N) Deuterium incorporation exchange at 10,
100, 1,000, and 10,000 s in the indicated peptides
derived from PKCi D223 (closed circles) and PKCi
1–587 (open circles).
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Mechanism of Allosteric Inhibition of aPKC1H was exchanged for 2H after prolonging the incubation time
to 166 min. Importantly, the same polypeptide derived from
the full-length protein exchanged fewer than 4 1H for 2H at
the first time point, indicative of a protection of more than 8
1H. Although this region was highly protected, we conclude
that it retained some degree of flexibility in the full-length pro-
tein because the protection was completely lost after 166 min
of incubation. This protection was observed in PKCi 1–587 in
overlapping polypeptides 285–306, 286–306, 288–308, and
290–303 (Figures 2B–2E), suggesting that amino acids 286–
308 afforded the majority of the protection. A second protected
amino acid sequence in the full-length protein comprised resi-
dues 355–370 (Figures 2F-2H), corresponding to the end of
helix aE and the following loop region on the large lobe below
helix aC (Figure 2A). In this case, two overlapping polypeptides
provided evidence for the protection of 2–3 1H after 166 min of
incubation in the deuterated solution. Another sequence with
low but reproducible protection from 1H/2H exchange corre-
sponded to polypeptide 376-390 (Figure 2I) and its overlapping
polypeptide 382-390 (Figure 2J), corresponding to a region that
links helix aC and the ATP-binding site and contains the DFG/
DYG motif. Finally, a second protected region (region 2) was
identified via the distinct 1H/2H exchange of a series of poly-
peptides comprising residues 405–448, which contains the
end of the activation loop, the P+1 loop (405–416 and 405–
417, Figures 2K and 2L), and helix aF (417–434 and 435–445,
Figures 2M and 2N), all of which are situated on the front of
the large lobe (Figure 2A).
Together, the results indicated that the N-terminal domains of
PKCi protected the catalytic domain from 1H/2H exchange in two
distinct regions, one centered on helix aC and the other corre-
sponding to the peptide-substrate binding region in protein
kinases.756 Chemistry & Biology 21, 754–765, June 19, 2014 ª2014 ElsevierIdentification of the PKCi Region Protected by the PSR
The PSR and the C1 domain are adjacent within the N terminus
of conventional, novel, and atypical PKCs (Figure 1B). The PSR
was thought to be the sole determinant of the intramolecular in-
hibition of PKC isoforms. However, we recently determined that
both the PSR and the C1 domain act together to inhibit and acti-
vate aPKCs (Lopez-Garcia et al., 2011), corresponding with a
model where the PSRprovides the highest affinity to the intramo-
lecular interaction. To probe the specific effect of the PSR on the
catalytic domain, we preincubated PKCi 1–587 and PKCi D223
with PSRtide (KSIYRRGARRWRKLYRA), a polypeptide derived
from the PSR, and subjected the samples to a time course of
1H/2H exchange, followed by standard 1H/2H exchange analysis.
The incubation of PKCi 1–587 (57 mM) with a 20-, 10-, or 5-fold
higher concentration of PSRtide triggered the precipitation of
the protein, thereby precluding further analysis. The precipitation
of concentrated PKCi 1–587 after the addition of PSRtide
indicated that the binding of PSR to full-length PKCi 1–587
decreased its stability in solution. On the other hand, we ob-
tained high-quality 1H/2H exchange data after preincubating
PKCi D223 with PSRtide (Figure 3). Most of the polypeptides
mapping to the catalytic domain of PKCi did not exhibit differ-
ences in the 1H/2H exchange rate in the presence or absence
of PSRtide. Notably, we observed that PSRtide significantly pro-
tected polypeptides 405–416 and 405–417 (Figures 3K and 3L)
that correspond to region 2 but not of region 1 polypeptides (Fig-
ures 3B–3J). The region 2 sequence is equivalent to a region in
PKA that interacts with the last seven amino acids of the pseudo-
substrate inhibitor protein kinase inhibitor, as observed in the
crystal structure of PKA in complex with ATP and protein kinase
inhibitor (Zheng et al., 1993). Therefore, the protection of these
region 2 polypeptides supports the hypothesis that the PSR in-
teracts with the substrate-binding site in PKCs. This is in furtherLtd All rights reserved
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Figure 3. Deuterium Incorporation Levels of
PKCi D223 in the Presence and Absence of
PSRtide
PKCi D223 was incubated in deuterated buffer in
the presence and absence of PSRtide, a synthetic
peptide derived from the pseudosubstrate region
of PKCz, and the exchange of hydrogen (1H) for
deuterium (2H) was analyzed by mass spectrom-
etry after protease cleavage. We identified poly-
peptides covering 81% of the isolated catalytic
domain of PKCi. Some polypeptides were pro-
tected from 1H/2H exchange upon treatment of the
PSRtide.
(A) Catalytic domain of PKCi (PDB code 3A8W),
indicating the location of polypeptides that were
protected from 1H/2H exchange.
(B–N) Deuterium incorporation at 1, 100,
1,000,and 10,000 s in the indicated peptides from
PKCi D223 incubated in the absence (closed
circles) and presence (open circles) of PSRtide.
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Mechanism of Allosteric Inhibition of aPKCagreement with PSRtide inhibiting PKCi D223 in a substrate-
competitive manner (Figure S4A) and with reports that show
that z inhibitory particle, the myristylated form of PSRtide, is
a high-affinity, substrate-competitive inhibitor of PKMz (Kd =
78 nM) (Yao et al., 2013). Importantly, the data also indicate
that the PSR does not directly or allosterically protect other
regions of the PKCi catalytic domain. Interestingly, neither the
magnitude nor the kinetics of the protection were similar to those
produced by the complete N-terminal region of PKCi, indicating
that other N-terminal regions were responsible for the enhanced
protection observed on overlapping peptides within residues
405–448.
The C terminus of the PSR is connected directly to the C1
domain, and our previous data indicated that it directly inter-
acted with the catalytic domain. When the PSR binds like a sub-
strate, the C1 domain is expected to be located to make direct
contact with the aCand aE helices. Together, the data presented
here support the contention that the extended protection
observed in region 1 (Figure 2A) is due to direct interaction of
the C1 domain with the aC helix. However, the low affinity of
the catalytic domain to the isolated C1 domain does not allow
us to experimentally test this interaction in parallel using 1H/2H
exchange. To better understand how the N-terminal region
affects the catalytic domain, we characterized the effects of
PSRtide and an ATP-competitive inhibitor on the thermal stability
of PKCi 1–587 and PKCi D223.
PSRtide Increases the Thermal Stability of PKCi D223
but Decreases the Stability of PKCi 1–587
We performed real-time thermal stability assays using Sypro Or-
ange, a temperature-stable fluorophore that exhibits enhanced
fluorescence upon interacting with unfolded proteins. Under
increasing incubation temperatures, PKCi 1–587 and PKCiChemistry & Biology 21, 754–765, June 19, 2014D223 produced distinct fluorescence
emission curves, indicating that they
differ in their unfolding patterns. The ther-
mal stability curves for PKCi 1–587 were
more complex than those produced byPKCi D223 (Figure S4B), which was expected because PKCi
1–587 is a multidomain protein. We evaluated the thermal shift
and the effect of additives on the thermal stability of the PKCi
constructs. As a control, we tested the effect of the nonspecific
ATP-competitive inhibitor staurosporine on the stability of PKCi
1–587 and PKCi D223. Staurosporine induced an 8C increase in
the thermal stability of both proteins, suggesting that the do-
mains N-terminal to the catalytic domain do not cooperate with
the ATP-binding site to provide additional stability (Figure 4A).
In the established stability assay, an excess of PSRtide
increased the melting temperature of PKCi D223 by 3C. In
contrast, under the same conditions, PKCi 1–587 was destabi-
lized by PSRtide by approximately 4C (Figure 4A). This differ-
ence corresponds with the destabilizing effect of PSRtide on
PKCi 1–587 observed in the 1H/2H exchange experiments. We
hypothesize that the stability provided by the binding of PSRtide
to the catalytic domain of PKCi 1–587 is negated by the
decrease in stability stemming from the concomitant displace-
ment of other N-terminal regions. The effect is compatible with
a model where, when PKCi 1–587 is in the inactive state, the
C1 domain is responsible for the large interaction surface
observed in region 1 when the contiguous PSR is correctly posi-
tioned at the substrate-binding site. The displacement of the
PSR upon the addition of PSRtide reduces the interaction of
the C1 domain with the catalytic domain.
Mechanism of Inhibition by Allosteric PIF-pocket
Binding Compounds
Throughout the years, we built a focused library of compounds
directed to the PIF-pocket of AGC kinases. The original com-
pounds were obtained by in silico screening for compounds
predicted to bind to the PIF-pocket of the active structure of
PKA and were characterized as allosteric activators of PDK1ª2014 Elsevier Ltd All rights reserved 757
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Figure 4. Effects of Ligands on Thermal Sta-
bility and Kinase Activity of PDK1 and PKCi
The thermal stability of PKCi D223, PKCi 1–587,
dmPDK1, and dmPDK1-z in the absence and
presence of ligand was assessed by differential
scanning fluorimetry (see also Figure S4). For each
kinase, the midpoint temperature of transition was
calculated in the absence (T0) or presence (Tm) of
ligand. The presented shift in thermal stability
(DTm = Tm  T0) of the proteins is the average
of two experiments. The kinase activity of PDK1
and PKCi was measured in vitro using T308tide
or MBP as a substrate. Data are presented as
means ± SEM.
(A) Effect of 100 mM PSRtide or 20 mM staur-
osporine on the thermal stability of full-length PKCi
(PKCi 1–587) or its catalytic domain (PKCi D223).
(B) Effect of 75 mM PS314 and PS315 on the
thermal stability of PKCi D223, PKCi 1–587,
dmPDK1, and dmPDK1-z and effect of 400 mM
PS48 on the thermal stability of dmPDK1 and
dmPDK1-z.
(C) Chemical structures of PS compounds.
(D) Effect of 100 mMPS315 on the kinase activity of
PKCi D223, PKCi 1–587, PKCz D241, PKCz 1–592,
dmPDK1, and dmPDK1-z.
(E) Inhibition of PKCz and PKCi by PS315.
(F) Effect of 100 mM PS48 on the kinase activity of
dmPDK1 and dmPDK1-z and effect of 100 mM
PS168 on the kinase activity of dmPDK1-z.
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Mechanism of Allosteric Inhibition of aPKC(Engel et al., 2006). Follow-up compounds in the library were
designed based on the initial hits and by scaffold hopping, keep-
ing a fixed angle between the two main ring systems to occupy
the two subpockets present in the PIF-pocket of active AGC
kinases. Upon investigating the effect of the compounds on
different AGC kinases, we completed our library by synthesizing
variants from activators and inhibitors (i.e., Fro¨hner et al., 2011;
Stroba et al., 2009; Wilhelm et al., 2012). By screening our
focused compound library for the ability to inhibit PKCz D241
activity, we identified a small molecule, PS315 (Figure 4C), that758 Chemistry & Biology 21, 754–765, June 19, 2014 ª2014 Elsevier Ltd All rights reservedinhibited the isolated catalytic domains
of PKCz and PKCi equally in vitro.
PS315wasderived fromPS48 (Figure 4C,)
(Hindie et al., 2009)), which did not affect
the activity of aPKCs in vitro. In U937
cells, PKCz is required for tumor necrosis
factor-a (TNF-a)-induced NF-kB activa-
tion (Levy et al., 2011; Mu¨ller et al.,
1995). We therefore employed a lucif-
erase reporter of NF-kB activation in
U937 cells to screen the effect of different
active compounds in a cellular setting, as
we performed previously (Fro¨hner et al.,
2011). Preincubation of U937 cells with
5 mM PS315 inhibited TNF-a induced
NF-kB activation by 74%, whereas com-
plete inhibition was observed with 10 mM
PS315 (Figure S5). Because PS315 was
cell-permeable and gave consistent
results in a cell culture model system,we selected PS315 to investigate the mechanism of inhibition
of aPKCs in vitro. PS315 inhibited all constructs of aPKCs tested
(Figure 4D). In vitro, PS315 inhibited the full-length and catalytic
domain constructs of PKCz (half maximal inhibitory concentra-
tion (IC50) = 10 mM) and PKCi (IC50 = 30 mM, Figure 4E). PS315
is a derivative of PS48, a compound that we showed previously
to bind to the PIF-pocket and activate protein kinase PDK1 (Hin-
die et al., 2009). Therefore, we investigated whether PS315 pro-
duced the inhibition by interaction with the PIF-pocket of aPKCs.
PS315 did not increase the thermal stability of PKCi 1–587 or
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Figure 5. Binding Modes of the Allosteric Compounds PS315 in dmPDK1-z and PS48 in dmPDK1
(A) Cartoon representation of the PIF-pocket in the crystal structure of dmPDK1 (Hindie et al., 2009) (PDB code 3HRC). The eight residues mutated to mimic the
PIF-pocket of PKCz are highlighted as purple sticks. The introduced residues are shown as pink sticks.
(B) PIF-pocket of PS48-bound dmPDK1. The allosteric compound PS48 is depicted in yellow. Interacting residues are shown as sticks.
(C) PIF-pocket of the dmPDK1-z (pink) binding compound PS315 (represented as beige sticks). Important residues are depicted as sticks. The mutation of
Phe157 (purple) to Leu opens up a tunnel to the active site of the kinase.
(D) Cut through a surface representation of dmPDK1 (carbon atoms in gray, nitrogen in blue, oxygen in red). PS48 and ATP are shown as sticks in their respective
binding pockets.
(E) Cut through the small lobe of PS315-bound dmPDK1-z, showing the tunnel between the PIF-pocket and ATP-binding site. The j2FOFCj electron density map
of PS315 is contoured at 1s.
(F) Superimposition of the structures of PS48-bound dmPDK1 (purple) and PS315-bound dmPDK1-z (pink) with focus on the interface between the active site and
the tunnel to the PIF-pocket. Compound PS315 causes the εamino group of Lys111 to be unresolved and to lose its salt bridges with Glu130 and the
a-phosphate of ATP. Furthermore, conformational changes of Ser92 and Phe93 in the Gly-rich loop were observed.
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Mechanism of Allosteric Inhibition of aPKCPKCi D223. Instead, it decreased the thermal stability of both
PKCi constructs with a more significant destabilization of the
full-length PKCi construct (Figure 4B). This was distinct from
the primarily stabilizing effect of staurosporine, which inhibits
kinases by occupying the ATP-binding site. To control for selec-
tivity, we determined that PS314, a diastereomer of PS315, did
not alter the stability of PKCi.
Crystal Structure of Allosteric Compound PS315 in
Complex with a PDK1/PKCz Chimera
To provide more conclusive evidence for the PS315 binding site
and to study its mechanism of inhibition, we attempted to crys-
tallize PS315 in complex with PKCz and PKCi, although without
success. In our previous studies on PDK1 and PS48, we ob-
tained crystals of the complex only after mutating two residues
in helix aG (Tyr288Gly and Gln292Ala) of PDK1 50–359 (Hindie
et al., 2009). The double mutant protein (dmPDK1 50–359) crys-
tallized in a novel crystal packing (crystal packing II) that allowed
for both cocrystallization with and soaking of PS48 into the PIF-
pocket. The small conformational changes observed did not
disturb the crystal. We also mutated eight residues within the
PIF-binding pocket of GST-PDK1 1–556 tomimic the PIF-pocketChemistry & Biology 21,of PKCz, producing a protein chimera that was inhibited by
PS168 (Lopez-Garcia et al., 2011). Similarly, we introduced the
eightmutations in the PIF-pocket of dmPDK150–359 (Figure 5A).
The resulting chimera (dmPDK1-z) was inhibited by PS168 (Fig-
ure 4F). Furthermore, although dmPDK1 50–359 was not
affected by 100 mM PS315, dmPDK1-z was inhibited by 50%
(Figure 4D). Interestingly, PS48 activated dmPDK1 50–359 but
had no effect on dmPDK1-z, suggesting that the mutations in
the PIF-pocket of dmPDK1 50–359 altered the selectivity of the
PIF-pocket and its specific effects on the activity from PDK1 to
that of aPKCs. Most notably, dmPDK1-z crystallized in crystal
packing II, and the structure of this protein in complex with
PS315 was obtained. The structures of dmPDK1-z (1.35 A˚ reso-
lution; R factor, 0.20; Rfree, 0.21) and dmPDK1-z/PS315 (1.9 A˚
resolution; R factor 0.18; Rfree, 0.22; Tables S1 and S2) were
solved by molecular replacement based on the structure of
dmPDK1 50–359 (Protein Data Bank [PDB] code 3HRF; Hindie
et al., 2009). The crystal structure of the complex revealed that
PS315 is bound in the PIF-pocket of the dmPDK1 50–359-z
chimera (Figures 5C, 5E, and 5F), therefore establishing
the PIF-pocket as the allosteric binding site of PS315. The
dmPDK1-z structure showed veryweak and intermittent electron754–765, June 19, 2014 ª2014 Elsevier Ltd All rights reserved 759
AB
Figure 6. Effect of PS315 on the Activity of PKCi D223 DHM and on
the Interaction with the PSR-C1 Domains
(A) Regulation of the kinase activity of PKCi by PS315. The kinase activity of
PKCi D223 and PKCi D223 DHM was measured in vitro using MBP as a sub-
strate. The kinase activity of PKCi D223 DHM missing the C-terminal region,
including the HM, was more strongly inhibited by PS315 than by PKCi D223.
(B) Interaction of the isolated PSR-C1 domain of PKCi with its catalytic
domain. The AlphaScreen interaction assay shows the binding of 18 nM GST-
PSR-C1 (PKCi 100–185) to 25 nM His-PKCi D223. This interaction was
strongly diminished upon addition of PS315. In contrast, PS314 was not able
to displace the interaction. Data are presented as means ± SEM (**p < 0.01;
***p < 0.001).
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pocket. Thus, this region could not be modeled reliably. Notably,
this region was well resolved and, thus, stabilized in the PS315-
bound structure. Strong and unambiguous electron density was
observed for the biphenyl and carboxylate moieties of PS315. A
weaker density was obtained for the p-chlorophenyl group in the
shallow part of the PIF-pocket.
Previously published crystal structures of PKCi demonstrated
that the HM, which is located within the C-terminal extension of
the catalytic core, binds to the PIF-pocket (Messerschmidt et al.,
2005; Takimura et al., 2010). Therefore, the binding of PS315
to the same site must induce a displacement of the C-terminal
region from its position. Thus, the inhibition of PKCi by PS315
might be due to a loss of activation by the displacement of the
C-terminal region that results from the movement of the HM
away from its binding site by PS315. To test this possibility, we
expressed amutant form of PKCi D223 lacking the last 31 amino
acids (PKCi D223 DHM, Figure 1B). PKCi D223 DHM was active
and inhibited by PS315 (Figure 6A). Therefore, the data indicated
that inhibition by PS315 was not mediated by the displacement
of the HM of PKCi from its binding site in the PIF-pocket. In addi-
tion, our data show that PS315 inhibited PKCi D223 DHM better
than PKCi D223 (Figure 6A), suggesting that, when the HM is not
bound to the PIF-pocket, PS315 has an increased ability to bind
and inhibit PKCi. Interestingly, the data further suggest that PKCi
does not rely much on the interaction between the HM and
its PIF-pocket for activity. This finding is in agreement with our
previous report showing that mutation of the HM Glu579 to Ala
had approximately the same specific activity as the wild-type
enzyme (Balendran et al., 2000). Furthermore the finding concurs
with our observation that antibodies that specifically recognize
the Phe residues within the HM of aPKCs did not significantly
inhibit the activity of aPKCs (L.A.L.G. and R.M.B., unpublished
data).
PS315 binds to the dmPDK1-z chimera in a similar manner
as PS48 binds to PDK1 (Hindie et al., 2009) (Figures 5B and
5C; Table S3), which is reminiscent of the binding mode of the
C terminus of AGC kinases to their corresponding PIF-pockets.
However, the C-termini of AGC kinases are typically necessary
for kinase activity, and PS48 promoted the activity of PDK1,
whereas PS315 negatively influenced kinase activity. Therefore,
we investigated potential molecular explanations for the diver-
gent effects on kinase activity. We compared the crystal struc-
ture of dmPDK1 50–359 with that of PS315 in complex with
the dmPDK1-z chimera. The superimposition of the two struc-
tures shows that the secondary structures match each other
throughout the whole structure, suggesting that the allosteric
effects that inhibit the kinase do not require major structural
changes (Figure S6).
The chemical structures of PS48 and PS315 differ by the pres-
ence of an additional phenyl ring (Figure 4C) that occupies a novel
deep pocket proximal to the ATP-binding site (Figures 5C and
5E). This could be facilitated in the dmPDK1-z chimera by the
presence of a mutation that replaces Phe157 with a shorter Leu
residue. However, PKCi has a Phe residue at the same position
and is also inhibited by PS315 (Figure 4D), suggesting that a
similar pocket can form in solution in the presence of a Phe res-
idue. Such an opening is easily envisaged based on our 1H/2H
exchange experiments, which demonstrated that helix aC wasLtd All rights reserved
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ures 2B and 2E). Additionally, by entering deeper into the struc-
ture, the biphenyl group would have sterically clashed with the
sidechain of thehighly conservedLys111,whichhas a salt bridge
interactionwithGlu130and thea- andb-phosphatesofATP in the
active structures of protein kinases. In the PS315-bound struc-
ture, however, the ε-amino group of Lys111 is unresolved, indi-
cating that the salt bridge that positions ATP for catalysis is
affected allosterically by the binding of PS315 to the PIF-pocket.
In comparisonwith thePS48-bound dmPDK1 structure, residues
Ser92 and Phe93 on the Gly-rich loop also underwent a confor-
mational transition (Figure 5F). The Ser92 side chain rotated
90C and lost its H bond to the ATP molecule, and Phe93
rotated 90C around Cc toward PS315. Altogether, we
conclude that the largest effect of PS315 on kinase activity is
due to the disruption of the stabilizing salt bridges that position
the ATP molecule optimally for catalysis.
Interestingly, PS48 and PS315 induced very different effects
on key residues in the PIF-pocket that could potentially also ac-
count for their different effects on activity. An important feature of
PS48 is that it tethers the C-terminal part of helix aC to the b
sheet on the opposite side of the PIF-pocket by its network of
interactions (Hindie et al., 2009). In particular, the carboxylate
of PS48 stabilized residues Arg131, Lys76, and Thr148 and con-
tactedGln150 through awater molecule. In contrast, the carbox-
ylate group of PS315 stabilized only the side chain of Lys131
(Figure 5C). However, in comparison with apo dmPDK1-z, its
presence stabilizes helix aB and loop aB/aC. The binding
of PS48 also allosterically stabilized the activation loop and
the DFG motif. However, most residues within the activation
loop are positioned identically between the PS48- and the
PS315-bound structures, suggesting that the binding of PS48
or PS315 promoted similar allosteric effects on the activation
loop, therefore discarding this region as a key mediator of the
allosteric inhibition by PS315.
Deuterium exchange experiments with dmPDK1-z in the
presence or absence of PS315 identified a single polypeptide
(108–134) that was protected in the presence of this compound.
This polypeptide corresponded to helix aC (Figure S7). This
result confirmed that the PIF-pocket was the binding site
for PS315 in solution. In addition, the data obtained in solution
confirm that no large conformational change in the chimera
occurs upon interaction with PS315. Together with the crystal
structure, these data suggest that inhibition by PS315 does not
produce major conformational changes and concur with the
above data indicating that PS315 subtly affected the catalytic
mechanism of the enzyme.
PS315Allosterically Affects the Interaction between the
PSR and the C1 Domain
We examined the effect of PS315 on the interaction between
His-PKCi D223 and the isolated N-terminal region of PKCi
fused to glutathione S-transferase (GST) (GST-PSR-C1) using
AlphaScreen technology (Lopez-Garcia et al., 2011). The inter-
action between the N-terminal region of PKCi and PKCi D223
was readily observed. Notably, PS315 displaced this interaction
in a concentration-dependent manner (Figure 6B), suggesting
that the presence of compounds in the PIF-pocket of PKCi
can stabilize conformations that affect the binding of the PSRChemistry & Biology 21,and C1 domains. We showed previously that this interaction
could be displaced by HM polypeptides (Lopez-Garcia et al.,
2011). The high concentration of PS315 required for displacing
the allosteric interaction resembles the concentrations needed
to displace the PDK1-PIFtide interaction with small compounds
(Busschots et al., 2012). In this case, the high concentrations
may be required because PSRtide may stabilize a closer active
conformation of helix aC, hindering the binding of PS315. Inter-
estingly, the current finding shows that the binding of a small
molecule specifically to the PIF-pocket can already produce
this subtle allosteric effect, which inhibits the binding of the
PSR and C1 domains to the catalytic domain.
DISCUSSION
Protein kinases play critical roles in the regulation of cellular ac-
tivities. Therefore, protein kinases have evolved stringent regula-
tion mechanisms. Notably, dysregulation of protein kinases is at
the center of numerous human diseases, making protein kinases
high-priority targets in drug discovery programs. However, most
drug development efforts target the highly conserved ATP-bind-
ing site of protein kinases, resulting in nonselective inhibitors
that target multiple protein kinases. As an alternative, there is
increasing interest in the development of non-ATP-competitive
regulators of protein kinases. A major impediment, however, is
the lack of a complete understanding of alternative drug-binding
sites on protein kinases. This work confirms that the PIF-pocket
has a central role in the regulation of aPKCs by N-terminal do-
mains and further shows that the helix aC lining the PIF-pocket
is highly flexible in solution and is protected by the inhibitory N
terminus but not by the PSR. We further show that PS315
allosterically inhibits aPKCs by occupying the PIF-pocket and
exploiting an additional deep subpocket that is also available
for PS315 interaction in a cellular environment. Moreover, we
demonstrate that it is possible to mutate the PIF-pocket of
PDK1 to mimic the PIF-pocket of another AGC kinase. Together,
this study describes the allosteric mechanism of inhibition
of aPKCs by N-terminal domains and small allosteric inhibitors
targeting the PIF-pocket. Importantly, this work presents an
approach using dmPDK1 50–359 as a scaffold to investigate
the molecular mode of action of small allosteric molecules bind-
ing to the PIF-pocket. We envisage that an analogous approach
will help to understand the allosteric mechanisms operating in
other protein families and how these mechanisms can be tar-
geted rationally for development of small-molecule allosteric ag-
onists and antagonists. Interestingly, themechanism of inhibition
by the N-terminal domain affecting the conformation of helix aC
resembles that of PKB/Akt, where the pleckstrin homology
domain inhibits activity by stabilizing helix aC of the PIF-pocket
in an inactive conformation (Wu et al., 2010). Therefore, besides
targeting of the PIF-pocket from the ‘‘inside’’ of the PIF-pocket,
our data suggest the alternative possible development of allo-
steric inhibitors with a mode of action similar to those developed
successfully for PKB/Akt.
Over the last 20 years, we have gained important insight into
the structure of the catalytic domain of diverse protein kinases
via protein crystallography. In contrast, comparably little is
known about the dynamics of the catalytic domain of protein
kinases in solution. With the 1H/2H exchange method, we754–765, June 19, 2014 ª2014 Elsevier Ltd All rights reserved 761
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Figure 7. Graphic Model of aPKC Regula-
tion by N-terminal Domains and Allosteric
Inhibition by PS315
(A) The structural models of the different domains
of an active aPKC are shown as a surface repre-
sentation. The C-terminal region (red) comprising
the HM in the active structure of aPKCs is not
required for activity and may be in equilibrium
between unbound and bound to the PIF-pocket.
1H/2H exchange experiments suggest that the
helix aC is flexible in the active structure of the
catalytic domain.
(B) 1H/2H exchange experiments confirm that the
PSR binds at the peptide-substrate binding site
and suggest that the contiguous C1 domain in-
teracts with helix aC, protecting it from 1H/2H ex-
change. In this manner, the PIF-pocket appears as
a key feature of the allosteric inhibition of aPKCs
by N-terminal domains. In the full-length protein,
the C-terminal region is protected from 1H/2H ex-
change. The mechanism of this protection is not
clear. The PSR not only participates in the inhibi-
tion of the activity, but it is also required for the
activation by phospholipids (Lopez-Garcia et al.,
2011).
(C) PS315 inhibits aPKC by occupying the PIF-
pocket and by allosterically affecting the key
residue Lys111 at the active site. PS315 binds
similarly as the previously described PS48 but, in
addition, occupies a deep tunnel behind helix aC
that is absent in the structure of active kinases.
PS315 binding displaces the C-terminal HM from
the PIF-pocket and also allosterically disrupts the
interaction between the PSR-C1 domains and the
catalytic domain.
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solvent, providing valuable information on the dynamics of the
different regions of the kinase. Notably, in the active aPKC pro-
tein, helix aC appeared to be highly exposed to solvent, more
similar to the behavior of a loop region than to that of a stable
a helix. The finding of the flexibility of helix aC and its stabilization
by the N-terminal domains confirm the importance of helix aC in
the molecular mechanism of regulation of PKCi. Helix aC forms
an essential part of the PIF-pocket, a site that we characterized
as a key regulatory site for the activation of a number of AGC ki-
nases via an intramolecular interaction with a phosphorylated
hydrophobic motif. Interestingly, PS315 benefits from the phys-
iological allosteric mechanism of regulation of PKCi. Most
notably, the flexibility of helix aC opened a deep tunnel and
enabled PS315 to directly disrupt the conserved active site
Lys-Glu pair that positions the a- and b-phosphates of ATP in
all protein kinases. Together, our study provides crystallographic
and dynamic structural data that demonstrate how the PIF-
pocket can regulate AGC kinases for allosteric activation and
allosteric inhibition of kinase activity and how small molecules
can exploit these allosteric mechanisms pharmacologically
(Figure 7).762 Chemistry & Biology 21, 754–765, June 19, 2014 ª2014 Elsevier Ltd All rights reservedPKCi, like most other protein kinases
within the AGC group, possesses an
equivalent hydrophobic motif locatedC-terminal to the catalytic domain, although the phosphorylat-
able residue is replaced by the acidic Glu amino acid. Interest-
ingly, the deletion of a large part of the C-terminal region that
includes the hydrophobic motif (PKCi D223 DHM) only minimally
affected the activity of PKCi, suggesting that this region does not
have a major role in the activation of this kinase. This agrees with
previous data showing that the mutation of the hydrophobic Glu
to Ala did not affect the specific activity of the other atypical PKC
isoform (Balendran et al., 2000). In addition, one crystal structure
of the catalytic domain of PKCi (PDB code 1ZRZ) shows that the
C-terminal region has high B-factors, likely because of its labile
interaction with the catalytic domain (Messerschmidt et al.,
2005). Finally, this flexibility of the C terminus corresponds with
our findings that a small molecule can displace the interaction
between the C-terminal hydrophobic motif and the PIF-pocket
of aPKCs. Interestingly, in contrast to a role in kinase activity or
activation, the C-terminal region of PKCi was protected from
1H/2H exchange by the N-terminal domains, indicating that this
C-terminal extension of the catalytic core is stabilized by the
N-terminal domains and may play a role in the inhibition of
PKCi. Our data do not discard that the hydrophobic motif of
PKCimay remain bound to the PIF-pocket of PKCi in the inactive
Chemistry & Biology
Mechanism of Allosteric Inhibition of aPKCstructure of the full-length kinase. Recent structural work on the
classical PKCb II isoform revealed an intramolecular interaction
of the catalytic domain with the C1B domain and a crystal con-
tact interaction with the C2 domain (Leonard et al., 2011). We
cannot foresee that any of these interactions are conserved
in aPKCs because these domains do not have equivalents in
aPKCs. The C1 domain from PKCb that is equivalent to the atyp-
ical C1 domain of aPKCs is the C1A domain because this is the
C1 domain directly connected to the PSR (Figure 1B).
We and others previously developed allosteric activators
of protein kinase PDK1 (Busschots et al., 2012; Engel et al.,
2006; Hindie et al., 2009; Sadowsky et al., 2011; Stockman
et al., 2009; Stroba et al., 2009; Wei et al., 2010). Previous
in vitro studies demonstrated that the PIF-pocket of AGC
kinases had the potential to transduce kinase inhibition. Diverse
AGC kinases were partially inhibited by a non-phosphorylated
HM polypeptide (Fro¨din et al., 2002). A PIF-binding pocket
mutant of PDK1 (PDK1[Thr148Val]) was inhibited instead of
being activated (Engel et al., 2006) by the standard activating
polypeptide PIFtide (Biondi et al., 2000), and mutation of
Thr148 to Cys in PDK1 and subsequent covalent modification
by disulfide-trapping a small molecule fragment partially in-
hibited PDK1 (Sadowsky et al., 2011). The allosteric inhibitors
of aPKCs demonstrate that the PIF-pocket can be targeted
with reversible small molecules to regulate AGC kinases. PKCi
is a validated drug target for the treatment of lung, pancreatic,
and ovarian cancers (Fields et al., 2007; Murray et al., 2011),
is upstream of hedgehog signaling in cancer (Atwood et al.,
2013), and is necessary for cancer stem cells (Regala et al.,
2009). The concentrations of PS315 that were active in vitro
were similar to those concentrations that produced effects in
U937 cells in culture. We cannot rule out that the effect on
U937 cells may be mediated by nonspecific effects. However,
we should note that an increased potency in cells is not surpris-
ing for allosteric inhibitors. Indeed, this is the case for PD098059
(Dudley et al., 1995), a MEK-1 inhibitor that is vastly more
potent in cells than in vitro on the phosphorylated active kinase
because it binds preferentially to an inactive—not phosphory-
lated—conformation of the kinase. Together, these data justify
the development of more potent derivatives of PS315 with the
potential to become cancer therapeutics. A major advancement
in the understanding of the mode of binding and of allosteric in-
hibition of PS315 was obtained from the crystallographic data.
Because it was not possible to obtain crystallography data on
PKCi, we tested an approach that utilized dmPDK1 50–359 as
a scaffold. The data presented here demonstrate that the muta-
genesis of the PIF-pocket residues of PDK1 to those of aPKC
converted PDK1 into a protein that was regulated allosterically
by small-molecule allosteric inhibitors of aPKCs. Moreover,
similarly to dmPDK1 50–359, the dmPDK1-z chimera crystal-
lized readily and provided the appropriate scaffold to mimic
the PIF-pocket site of aPKCs. This approach may, therefore,
support drug development focusing on the PIF-pocket of AGC
kinases.
This work provides structural insight into the binding mode of
low molecular weight allosteric inhibitors that bind to the PIF-
pocket of PKCi and will support the development of more potent
and selective compounds for the treatment of diseases where
PKCi is a validated drug target, such as cancer.Chemistry & Biology 21,SIGNIFICANCE
The transmission of information in cell signaling often
involves allosteric on-off switches. Understanding those
mechanisms and how to pharmacologically modulate the
switches will enable the development of innovative medi-
cines. Protein kinases are model allosteric proteins that
regulate cellular functions and are, therefore, physiologi-
cally tightly regulated. It is of interest to pharmacologically
modulate the on-off switch in protein kinases for the treat-
ment of human diseases. aPKC is a target for the treatment
of cancers. We describe here that the regulation of aPKCs
involves the regulation of the dynamics of the aC helix and
the PIF-pocket. The small allosteric inhibitor PS315 and the
N-terminal region of aPKC both act directly on the PIF-
pocket on-off switch. PS315, binding at the PIF-pocket, in-
duces a displacement of the active site residue Lys111,
thereby inhibiting the activity of aPKCs by allosterically
affecting the catalytic mechanism of the kinase. We show
here that the allosteric inhibitor profits from the dynamic
nature of the regulatory PIF-pocket on-off switch. An under-
standing of the regulation of kinases and of the action of
allosteric modulators will support drug development for
aPKCs and other allosteric proteins.
EXPERIMENTAL PROCEDURES
Materials
A list of materials and polypeptides used and the full description of the synthe-
sis and characterization of PS315 is presented in Supplemental Experimental
Procedures.
Expression and Purification of the Protein Kinases
Protein kinases used for crystallographic studies and 1H/2H exchange
experiment were produced in Sf9 cells and purified essentially as described
previously (Hindie et al., 2009). The dmPDK1-z plasmid was prepared by
site-directed mutagenesis. Further information is detailed in Supplemental
Experimental Procedures.
Protein Kinase Activity Assay
The protein kinase activity assays were performed as described previously
using MBP or a variant of PSRtide where a single Ala is replaced with Ser as
the aPKC substrate (Lopez-Garcia et al., 2011) and T308tide for PDK1 (Biondi
et al., 2000; Engel et al., 2006). The protein kinase and substrate mixture was
preincubated with either small molecules or lipid activator. Further information
is detailed in Supplemental Experimental Procedures.
1H/2H Exchange Assay
The protein kinase sample was incubated in deuterium oxide (2H2O) buffer at
0C for the stated incubation times. The exchange was stopped by quenching
with acid. The sample was snap-frozen and stored in liquid nitrogen prior
to analysis. The labeled proteins were digested with pepsin, and the labeled
derivative peptides were analyzed by liquid chromatography and mass spec-
trometry to determine their deuterium content. The graphics represent the
number of deuterium atoms incorporated into each peptide during the stated
incubation time in deuterated buffer. Each time curve is the average result of
two replicates. Further information is detailed in Supplemental Experimental
Procedures.
Crystallization of dmPDK1-z
dmPDK1-z was crystallized by hanging drop vapor diffusion at 20C. 1.5 ml of
protein (23 mg/ml) was added to 1.5 ml of reservoir solution (1.25 M sodium
citrate, 100 mM HEPES (pH 7.5), and 10 mM dithiothreitol) and 0.3 ml of 1 M
ammonium sulfate. Crystals grew to a size of 300 3 300 3 80 mm within754–765, June 19, 2014 ª2014 Elsevier Ltd All rights reserved 763
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Mechanism of Allosteric Inhibition of aPKC2–3 weeks. For the PS315-bound structure, crystals were soaked for 18 hr in
reservoir solution containing 1.5 mM PS315.
Data Collection, Structure Solution, and Refinement
X-ray diffraction data were collected at beamline PXIII (Swiss Light Source).
Data were processed and scaled using the XDS program package (Kabsch,
1993). The structure of dmPDK1 50–359 (PDB code 3HRC) (Hindie et al.,
2009) served as a model in molecular replacement using Phaser (McCoy
et al., 2007). PHENIXwas used for refinement, including TLS protocols (Adams
et al., 2010). Coot was used for manual model building and structural analysis
(Emsley and Cowtan, 2004). Molecular graphic figures were prepared using
PyMOL (DeLano, 2002).
Thermostability Assay
The kinase thermostability assays were performed as described previously
(Niesen et al., 2007). Further information is detailed in Supplemental Experi-
mental Procedures.
In Vivo Effects of PS315
The NF-kB luciferase reporter assay was performed as described previously
(Lopez-Garcia et al., 2011). In short, U937cells were transiently transfected
with a plasmid encoding luciferase under the control of NF-kB response ele-
ments (pGL4.32 [luc2P/NF-kB-RE/Hygro], Promega). The cells were serum-
starved overnight and incubated in 96-well plates with PS315 or DMSO
(0.25%) for 1 hr before stimulation with TNF-a (50 ng/ml, PeproTech) for
90 min. Luciferase activity was measured using Bright-Glo luciferase assay re-
agent (Promega) as a substrate in an EnVision multilabel reader (Perkin Elmer).
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